报告显示，新产业公司前三季度营业收入为34.28亿元，同比增长0.39%；归母净利润为12.05亿元，同 比下降12.92%；扣非归母净利润为11.36亿元，同比下降14.68%；基本每股收益1.53元。 饶微，男，1964年出生，中国国籍，无境外居留权，工学博士。1997年加入新产业有限责任公司，后升 任总经理职务；2012年8月至今，担任新产业生物董事长兼总经理。 饶捷，女，1989年出生，中国国籍，无境外居留权，2013年毕业于深圳大学生物医学工程专业，硕士研 究生学历，生物医学工程工程师中级职称，深圳市坪山区高层次人才。2011年3月加入新产业，历任仪 器研发中心项目负责人、质量保证部经理、海外注册部经理；现任新产业公司总经理特别助理，分管质 量保证部和海外注册部；2024年1月至今，担任新产业生物董事。 据东方财富网数据，新产业董事长饶微2024年所获薪酬为447.1万元，相较上年薪酬459.2万元微降；董 事饶捷同年领薪120万元。 据瑞财经查阅，饶微与饶捷系父女关系。 瑞财经 钟鸣辰新产业(SZ300832)近日发布2025年三季报，前三季同比增收不增利。 2025年前三季度，新产业公司毛利率为 ...

Core Viewpoint - New Industry's stock price has shown fluctuations, with a recent increase of 2.00% and a total market capitalization of 48.887 billion yuan, despite a year-to-date decline of 10.54% [1] Financial Performance - For the period from January to September 2025, New Industry achieved a revenue of 3.428 billion yuan, reflecting a year-on-year growth of 0.39%, while the net profit attributable to shareholders decreased by 12.92% to 1.205 billion yuan [2] - Cumulative cash dividends since the A-share listing amount to 3.860 billion yuan, with 2.357 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders decreased by 15.87% to 13,100, with an average of 51,997 circulating shares per person, an increase of 18.87% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.2383 million shares, and new shareholder E Fund Blue Chip Select Mixed Fund, holding 1.10001 million shares [3] Stock Performance - The stock has experienced a 1.73% increase over the last five trading days, an 8.93% decline over the last 20 days, and a 14.69% increase over the last 60 days [1] Business Overview - New Industry, established on December 15, 1995, specializes in the research, development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents, with reagent sales contributing 69.62% to revenue [1] - The company operates within the pharmaceutical and biomedical industry, specifically in the medical device and in vitro diagnostics sectors [1]

Core Viewpoint - The company, established in 1995 and listed in 2020, is a leading player in the domestic chemiluminescence immunodiagnostic field, focusing on the development, production, and sales of fully automated chemiluminescence immunoassay instruments and related reagents [1] Group 1: Business Performance - In Q3 2025, the company's revenue reached 3.428 billion yuan, ranking first among 39 companies in the industry, with the second-ranked company, Antu Biology, at 3.127 billion yuan [2] - The net profit for Q3 2025 was 1.205 billion yuan, placing the company second in the industry, with the top company, Jiuan Medical, at 1.588 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 8.69%, an increase from 8.12% year-on-year, but still below the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 68.73%, down from 72.34% year-on-year, yet higher than the industry average of 56.20% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 15.87% to 13,100, while the average number of circulating A-shares held per shareholder increased by 18.87% to 52,000 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with 26.4824 million shares, an increase of 4.2383 million shares from the previous period [5] Group 4: Management Compensation - The chairman, Rao Wei, received a salary of 4.4712 million yuan in 2024, a decrease of 120,800 yuan from 2023 [4] Group 5: Market Outlook - According to Huazhang Securities, the company faced overall performance pressure in the first three quarters of 2025, but Q3 showed a significant recovery trend, with overseas main business revenue growing by 21.07% year-on-year [6] - The company is expected to achieve revenues of 4.567 billion, 5.211 billion, and 5.873 billion yuan from 2025 to 2027, with net profits of 1.761 billion, 2.001 billion, and 2.397 billion yuan respectively [6]

Core Viewpoint - New Industry's stock price has shown fluctuations with a recent increase of 2.06%, reflecting a total market capitalization of 53.31 billion yuan, while the company faces a decline in revenue and net profit year-on-year [1][2]. Financial Performance - For the first half of 2025, New Industry reported operating revenue of 2.185 billion yuan, a year-on-year decrease of 1.18%, and a net profit attributable to shareholders of 771 million yuan, down 14.62% compared to the previous year [2]. - The company's stock price has decreased by 2.44% year-to-date, with a 1.05% decline over the last five trading days, but has increased by 15.00% over the last 20 days and 23.07% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders for New Industry decreased by 19.09% to 15,600, while the average number of circulating shares per person increased by 23.59% to 43,743 shares [2]. - The company has distributed a total of 3.860 billion yuan in dividends since its A-share listing, with 2.357 billion yuan distributed over the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of June 30, 2025, Hong Kong Central Clearing Limited is the fifth largest with 22.2441 million shares, an increase of 11.0924 million shares from the previous period [3]. - Other notable institutional shareholders include Huabao Zhongzheng Medical ETF and Yifangda Growth Enterprise Board ETF, which have also increased their holdings [3].

Core Viewpoint - The company, Shenzhen New Industry Biomedical Engineering Co., Ltd., has shown a mixed performance in stock price and financial results, with a recent increase in stock price but a decline in revenue and net profit year-on-year [1][2]. Financial Performance - As of June 30, 2025, the company reported a revenue of 2.185 billion yuan, a year-on-year decrease of 1.18% [2]. - The net profit attributable to shareholders was 771 million yuan, reflecting a year-on-year decrease of 14.62% [2]. - The company has distributed a total of 3.860 billion yuan in dividends since its A-share listing, with 2.357 billion yuan distributed in the last three years [3]. Stock Market Activity - On September 11, the stock price increased by 2.05%, reaching 69.19 yuan per share, with a trading volume of 120 million yuan and a turnover rate of 0.26% [1]. - The total market capitalization of the company is 54.364 billion yuan [1]. - Year-to-date, the stock price has decreased by 0.52%, but it has increased by 6.73% over the last five trading days and by 20.75% over the last 20 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 19.09% to 15,600, while the average number of tradable shares per person increased by 23.59% to 43,743 shares [2]. - The top ten circulating shareholders include significant institutional investors, with Hong Kong Central Clearing Limited being the fifth largest shareholder, increasing its holdings by 11.0924 million shares [3].